Shilpa Medicare Ltd - 530549 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 31, 2019 for Deepak Kumar Inani Shilpa Medicare Ltd - 530549 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 31, 2019 for Ramakant Inani Shilpa Medicare Ltd - 530549 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 31, 2019 for Vishnukant Chaturbhuj Bhutada Shilpa Medicare Ltd - 530549 - Board Meeting Intimation for BOARD MEETING OF SHILPA MEDICARE LIMITED IS SCHEDULED TO BE HELD ON 9.11.2019 TO APPROVE THE QUARTERLY FINANCIAL RESULTS FOR QUARTER ENDED 30.09.2019.
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2019 ,inter alia, to consider and approve With reference to the subject cited above, we wish to inform you that a meeting of the Board of Directors of Shilpa Medicare Limited will be held on Saturday, the 09th day of November, 2019 to inter alia transact the following items of business: Approval of the unaudited Standalone and Consolidated financial results of the Company for the quarter and half year ended 30th September, 2019. Shilpa Medicare Ltd - 530549 - Intimation U/R 30 Of The SEBI(LODR) Regulations- Reg. Ref: Stock Code: NSE: SHILPAMED/BSE-530549
We hereby inform that the Company has received US FDA 'Establishment Inspection Report (EIR)' on 24 Oct 2019, for the Finished Dosage Formulation Facility (Sterile and Non-sterile Dosage Forms) located at S-20 to S-26, Pharmaceutical Formulations SEZ, APIIC, Jadcherla, Telangana State, India. The company's finished dosage form facility was inspected by US FDA from 29th August to 6th September, 2019. FDA has concluded the inspection, with determination that the inspection classification of this facility is "voluntary action indicated" ("VAI"). This facility is in acceptable state of compliance with regards to current good manufacturing practice (CGMP). This is for your information and doing the needful. SHILPA MEDICARE LTD. - 530549 - Intimation U/R 30 Of The SEBI(LODR) Regulations- Reg. Ref: Stock Code: NSE: SHILPAMED/BSE-530549
We hereby inform that the Company has received US FDA 'Establishment Inspection Report (EIR)' on 24 Oct 2019, for the Finished Dosage Formulation Facility (Sterile and Non-sterile Dosage Forms) located at S-20 to S-26, Pharmaceutical Formulations SEZ, APIIC, Jadcherla, Telangana State, India. The company's finished dosage form facility was inspected by US FDA from 29th August to 6th September, 2019. FDA has concluded the inspection, with determination that the inspection classification of this facility is "voluntary action indicated" ("VAI"). This facility is in acceptable state of compliance with regards to current good manufacturing practice (CGMP). This is for your information and doing the needful. Shilpa Medicare Ltd - 530549 - Compliance Certificate For Half Year Ended 30Th September, 2019 Compliance
With reference to the subject cited above, please find attached herewith the Compliance Certificate under Regulation 40(9) of SEBI (LODR) Regulations, 2015, issued by the Practicing Company Secretary M/s P.S Rao & Associates. Kindly take the same on record. Shilpa Medicare Ltd - 530549 - Shareholding for the Period Ended September 30, 2019
Shilpa Medicare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click here SHILPA MEDICARE LTD. - 530549 - Statement Of Investor Complaints For The Quarter Ended September 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1111 Name of the Signatory :- V V KRISHNA CHAITANYADesignation :- Company Secretary and Compliance Officer Shilpa Medicare Ltd - 530549 - Compliance Certificate For Half Year Ended 30Th September, 2019
This is to certify that the Company, M/s Shilpa Medicare Limited having its registered office at 12-6-214/A-1, Hyderabad Road, Raichur ,Karnataka - 584135 has been maintaining all the activities in relation to both physical and electronic share transfer facility as specified under Regulation 7(2) of SEBI (LODR) Regulations, 2015 with M/s Karvy Fintech Private Limited, a SEBI Registered Share Transfer Agent, having their corporate office at Karvy Selenium Tower B, Plot No.31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad - 500 032. Further, a copy of letter received from M/s Karvy Fintech Private Limited confirming the compliance of provisions of Regulation 7 (2) of the SEBI (LODR) Regulations, 2015, is enclosed herewith